Syntara Ltd Total Liabilities
Syntara Ltd total liabilities. Based on the latest financial reports, Syntara Ltd (SNT) has total liabilities worth AU$5.42 Million AUD (≈ $3.84 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Syntara Ltd (SNT) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Syntara Ltd (2003–2025)
Total liabilities of Syntara Ltd from 2003 to 2025. This chart illustrates how Syntara Ltd's total liabilities have evolved over time, based on quarterly financial data.
Syntara Ltd Competitors by Total Liabilities
The table below lists competitors of Syntara Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mountain Alliance AG
XETRA:ECF
|
Germany | €4.19 Million |
|
Kintech Electronics Co Ltd
TWO:6210
|
Taiwan | NT$124.90 Million |
|
Cruzados SADP
SN:CRUZADOS
|
Chile | CL$60.90 Billion |
|
Uniserve Communications Corp
V:USS
|
Canada | CA$11.22 Million |
|
Eastparc Hotel Tbk PT
JK:EAST
|
Indonesia | Rp24.07 Billion |
|
MegaMD Co. Ltd
KQ:133750
|
Korea | ₩16.86 Billion |
|
Deep Value Driller AS
OL:DVD
|
Norway | Nkr166.61 Million |
|
Milestone Scientific
NYSE MKT:MLSS
|
USA | $5.94 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Syntara Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Syntara Ltd (SNT) total assets.
Liquidity & Leverage Metrics
Syntara Ltd Total Liabilities Ratios Explained
Syntara Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Syntara Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Syntara Ltd (2003–2025)
The table below shows the annual total liabilities of Syntara Ltd from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$5.42 Million ≈ $3.84 Million |
-4.84% |
| 2024-06-30 | AU$5.70 Million ≈ $4.03 Million |
-60.59% |
| 2023-06-30 | AU$14.47 Million ≈ $10.24 Million |
+0.59% |
| 2022-06-30 | AU$14.38 Million ≈ $10.18 Million |
-53.22% |
| 2021-06-30 | AU$30.75 Million ≈ $21.75 Million |
-9.53% |
| 2020-06-30 | AU$33.98 Million ≈ $24.05 Million |
-10.22% |
| 2019-06-30 | AU$37.85 Million ≈ $26.78 Million |
-2.89% |
| 2018-06-30 | AU$38.98 Million ≈ $27.58 Million |
-7.00% |
| 2017-06-30 | AU$41.91 Million ≈ $29.66 Million |
-6.29% |
| 2016-06-30 | AU$44.73 Million ≈ $31.65 Million |
-3.27% |
| 2015-06-30 | AU$46.24 Million ≈ $32.72 Million |
-5.02% |
| 2014-06-30 | AU$48.68 Million ≈ $34.44 Million |
+9.68% |
| 2013-06-30 | AU$44.38 Million ≈ $31.41 Million |
+102.70% |
| 2012-06-30 | AU$21.90 Million ≈ $15.49 Million |
-7.77% |
| 2011-06-30 | AU$23.74 Million ≈ $16.80 Million |
-7.80% |
| 2010-06-30 | AU$25.75 Million ≈ $18.22 Million |
-2.11% |
| 2009-06-30 | AU$26.31 Million ≈ $18.61 Million |
+343.76% |
| 2008-06-30 | AU$5.93 Million ≈ $4.19 Million |
-2.64% |
| 2007-06-30 | AU$6.09 Million ≈ $4.31 Million |
+13.20% |
| 2006-06-30 | AU$5.38 Million ≈ $3.81 Million |
+127.09% |
| 2005-06-30 | AU$2.37 Million ≈ $1.68 Million |
+59.96% |
| 2004-06-30 | AU$1.48 Million ≈ $1.05 Million |
+144.96% |
| 2003-06-30 | AU$604.50K ≈ $427.72K |
-- |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more